Barclays PLC Has $1.02 Million Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Barclays PLC boosted its position in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 70.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,651 shares of the biotechnology company’s stock after purchasing an additional 38,321 shares during the period. Barclays PLC owned 0.16% of Astria Therapeutics worth $1,020,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its stake in shares of Astria Therapeutics by 152.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock valued at $3,460,000 after buying an additional 189,727 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Astria Therapeutics during the 3rd quarter worth approximately $613,000. FMR LLC increased its position in Astria Therapeutics by 29.2% in the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after acquiring an additional 1,767,714 shares during the period. Vestal Point Capital LP raised its stake in shares of Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after acquiring an additional 750,000 shares during the last quarter. Finally, Sofinnova Investments Inc. acquired a new position in shares of Astria Therapeutics during the second quarter worth $552,000. 98.98% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ATXS. Oppenheimer increased their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Monday. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Trading Down 1.2 %

Shares of ATXS opened at $7.37 on Wednesday. The firm’s fifty day simple moving average is $9.77 and its two-hundred day simple moving average is $10.69. Astria Therapeutics, Inc. has a 12 month low of $6.94 and a 12 month high of $16.90. The stock has a market capitalization of $415.92 million, a P/E ratio of -3.53 and a beta of 0.70.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.